Filter posts

Gene Patent Questions Remain: USPTO Issues Examiner Guidelines

The new Patent Office guidance, issued March 4, extends the Supreme Court’s legal logic into …

Patently Biotech’s Top Articles of 2013

Intellectual property featured prominently in 2013’s public discourse. Gene patents, patent trolls, India’s anti-patent actions, …

BIO IP & Diagnostics Symposium

BIO’s IP & Diagnostics Symposium (BIO IPDX) will review the current patent law landscape and …

Gene Patents, Angelina Jolie, and Reality

By Dr. Hans Sauer, J.D., Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization  Angelina …

Gene Patents: Common Sense from Down Under

Oh, crikey! The U.S. Supreme Court is currently reviewing briefs to consider whether preparations of …

Whole Genome Sequencing and Myriad Supreme Court Case: Nothing to See Here

Bio IT World just published an article stating that the Myriad Supreme Court case will …

AMP v. Myriad: BIO Statement on Federal Circuit (Re)Decision

BIO released the following statement on the Federal Circuit’s decision in the AMP v. Myriad …

The U.S. Government’s Position in ACLU v. Myriad Genetics

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property, comments on  the Department of Justice’s brief …

Gene Patent Discussion Should Include Industrial, Environmental, & Ag Biotech

Twenty-three industrial and agricultural biotech companies, ranging from development-stage businesses to all of the largest …

PTO Genetic Testing Study: What's Patents Got to Do with It

The USPTO held a hearing on February 16 to collect testimony from interested parties to …